NOXXON's Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference
NOXXON Pharma AG announced that Prof. Hermann Haller, Director of the Department of Nephrology and Hypertension at Hanno…
NOXXON Pharma AG announced that Prof. Hermann Haller, Director of the Department of Nephrology and Hypertension at Hanno…
NOXXON Pharma AG announced that Phase IIa proof-of-concept data from the emapticap pegol (NOX-E36) trial in diabetic nep…
NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial f…
NOXXON Pharma today announced the treatment of the first patient in a Phase IIa clinical trial of its anti-CCL2/MCP-1 (C…
Die Speedel Holding AG (SWX: SPPN) hat heute mitgeteilt, dass sie Daten für zwei Kandidaten ihrer Entwicklungspipeline a…
Speedel Holding Ltd. (SWX: SPPN) today announced that data for two of its developmental product candidates were presente…
Speedel Holding Ltd. (SWX: SPPN) highlighted today that Novartis is to expand the clinical trial programme with SPP100 (…
Speedel Holding Ltd. (SWX: SPPN) highlighted today that it is actively participating in Hypertension 2008, a joint meeti…
Die Speedel Holding AG (SWX: SPPN) hat heute über ihre aktive Teilnahme an dem Medizinkongress "Hypertension 2008" beric…
Data from the AVOID study published in this week's New England Journal of Medicine demonstrate that the first-in-class d…